¼¼°èÀÇ ¹æ»ç¼ºÀǾàǰ ½ÃÀå
Radiopharmaceuticals
»óǰÄÚµå : 1650693
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 739 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,171,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,515,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¹æ»ç¼ºÀǾàǰ ¼¼°è ½ÃÀå 2030³â±îÁö 143¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â 76¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¹æ»ç¼ºÀǾàǰ ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 143¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â µ¿¾È ¿¬Æò±Õ 11.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ SPECT ¹æ»ç¼ºµ¿À§¿ø¼Ò ºÐ¾ß´Â CAGR 10.4%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ Á¾·á ½ÃÁ¡¿¡ 62¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, PET ¹æ»ç¼ºµ¿À§¿ø¼Ò ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È 10.2%ÀÇ CAGR·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀå 37¾ï ´Þ·¯, Áß±¹Àº CAGR 13.9%·Î ¼ºÀå Àü¸Á

¹Ì±¹ÀÇ ¹æ»ç¼ºÀǾàǰ ½ÃÀåÀº 2024³â 37¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 12¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024-2030³â ºÐ¼® ±â°£ µ¿¾È CAGRÀº 13.9%¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 8.0%¿Í 8.7%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 9.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ¹æ»ç¼ºÀǾàǰ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

¹æ»ç¼ºÀǾàǰÀº ÀÇ·á ¿µ»ó°ú Ä¡·á¿¡ ¾î¶² Çõ¸íÀ» ÀÏÀ¸Å°°í Àִ°¡?

¹æ»ç¼ºÀǾàǰÀº ÀÇ·á ¿µ»ó ¹× Ä¡·á ºÐ¾ß¿¡ º¯È­¸¦ °¡Á®¿ÔÀ¸¸ç, ¾Ï, ½ÉÇ÷°üÁúȯ µî ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ °íµµÀÇ Áø´Ü ¹× Ä¡·á ¿É¼ÇÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹æ»ç¼º È­ÇÕ¹°Àº ÇÙÀÇÇп¡¼­ ºÐÀÚ ¼öÁØ¿¡¼­ Áúº´À» ½Ã°¢È­Çϰí, Áø´ÜÇϰí, Ä¡·áÇϱâ À§ÇØ »ç¿ëµË´Ï´Ù. ¾çÀüÀÚ¹æ»ç¼±´ÜÃþÃÔ¿µ(PET), ´Ü±¤ÀÚ¹æ»ç¼±Àü»êÈ­´ÜÃþÃÔ¿µ(SPECT) µîÀÇ ±â¼úÀº ¹æ»ç¼ºÀǾàǰÀ» ÀÌ¿ëÇÏ¿© ü³»ÀÇ ±¸Á¶¿Í ±â´É¿¡ ´ëÇÑ »ó¼¼ÇÑ ¿µ»óÀ» Á¦°øÇÕ´Ï´Ù. ¹æ»ç¼ºÀǾàǰÀÇ Á¤È®¼º°ú È¿°ú·Î Á¶±â ¹ß°ß°ú Ç¥Àû Ä¡·á°¡ °¡´ÉÇØÁ® ±âÁ¸ Ä¡·á¿Í ºñ±³ÇÏ¿© ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ°í ºÎÀÛ¿ëÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

¹æ»ç¼ºÀǾàǰÀÇ ±â¼úÀû, ±ÔÁ¦Àû ¹ßÀüÀ̶õ?

±â¼úÀÇ ¹ßÀüÀº ¹æ»ç¼ºÀǾàǰÀÇ °³¹ß ¹× ÀÀ¿ëÀ» Å©°Ô Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¹æ»ç¼º È­ÇÐ ¹× ¹æ»ç¼º Ç¥Áö ±â¼úÀÇ Çõ½ÅÀº ´Ù¾çÇÑ Áø´Ü ¹× Ä¡·á Àû¿ë¿¡ ÀÖ¾î º¸´Ù ƯÀÌÀûÀ̰í È¿°úÀûÀÎ È­ÇÕ¹°ÀÇ Ã¢ÃâÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ÇÏÀ̺긮µå PET/MRI ¹× PET/CT ½Ã½ºÅÛ°ú °°Àº À̹Ì¡ ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÇ·á¿ë À̹Ì¡ÀÇ Á¤È®µµ¿Í ÇØ»óµµ°¡ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© ¶ÇÇÑ ¹æ»ç¼ºÀǾàǰÀÇ ¾ÈÀüÇϰí È¿À²ÀûÀÎ °³¹ßÀ» Áö¿øÇϱâ À§ÇØ ÁøÈ­Çϰí ÀÖÀ¸¸ç, FDA ¹× EMA¿Í °°Àº ±â°üÀº »õ·Î¿î ¹æ»ç¼ºÀǾàǰÀÇ ½ÂÀÎÀ» À§ÇÑ °¡À̵å¶óÀΰú ½Å¼ÓÇÑ °æ·Î¸¦ ¸¶·ÃÇÏ¿© ÷´Ü ÀÇ·á±â¼ú¿¡ ´ëÇÑ Àû½Ã Á¢±ÙÀ» º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

¹æ»ç¼ºÀǾàǰÀº Á¾¾çÇаú ½ÉÀåÇп¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

Á¾¾çÇп¡¼­ ¹æ»ç¼ºÀǾàǰÀº Áø´Ü°ú Ä¡·á ¸ðµÎ¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¹æ»ç¼ºÀǾàǰÀº Á¾¾çÀ» Á¶±â¿¡ ¹ß°ßÇϰí Ä¡·á È¿°ú¸¦ ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ½À´Ï´Ù. ¹æ»ç¼º Ç¥Áö ´ÜŬ·ÐÇ×ü¿Í °°Àº Ä¡·á¿ë ¹æ»ç¼ºÀǾàǰÀº ÁÖº¯ °Ç°­ÇÑ Á¶Á÷ÀÇ ¼Õ»óÀ» ÃÖ¼ÒÈ­Çϸ鼭 ¾Ï¼¼Æ÷¿¡ Ç¥ÀûÈ­µÈ ¹æ»ç¼±À» Á¶»çÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ½ÉÀåÇп¡¼­ ¹æ»ç¼ºÀǾàǰÀº ½É±Ù °ü·ù ¹× »ýÁ¸ ´É·ÂÀ» Æò°¡ÇÏ¿© °ü»óµ¿¸Æ Áúȯ ¹× ±âŸ ½ÉÀå ÁúȯÀÇ Áø´Ü ¹× °ü¸®¿¡ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. Á¤È®ÇÑ Áø´Ü Á¤º¸¸¦ ¾ò°í Ç¥ÀûÈ­µÈ Ä¡·á¸¦ Á¦°øÇÏ´Â ´É·ÂÀº ÀÌ·¯ÇÑ Áß¿äÇÑ ÁúȯÀÇ °ü¸®¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù.

¹æ»ç¼ºÀǾàǰ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº?

¹æ»ç¼ºÀǾàǰ ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¾Ï°ú ½ÉÇ÷°üÁúȯÀÇ À¯º´·ü Áõ°¡´Â ÀÌ·¯ÇÑ Áúȯ¿¡ ´ëÇÑ °í±Þ Áø´Ü ¹× Ä¡·á ¼Ö·ç¼ÇÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. À̹Ì¡ ¹× ¹æ»ç¼ºÀǾàǰ °³¹ßÀÇ ±â¼ú ¹ßÀüÀº ÇÙÀÇÇÐ ½Ã¼úÀÇ Á¤È®¼º°ú È¿´ÉÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø°ú °£¼ÒÈ­µÈ ½ÂÀÎ ÀýÂ÷´Â »õ·Î¿î ¹æ»ç¼ºÀǾàǰÀÇ µµÀÔÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹æ»ç¼ºÀǾàǰÀº ȯÀÚ °³°³ÀÎÀÇ Çʿ信 µû¶ó ¸ÂÃãÈ­ÇÒ ¼ö Àֱ⠶§¹®¿¡ ¸ÂÃãÇü ÀÇ·áÀÇ È®»êµµ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇÙÀÇÇÐ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í ÀÇ·á ÀÎÇÁ¶óÀÇ È®Àåµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ¹æ»ç¼ºÀǾàǰ ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀå°ú Çõ½ÅÀ» º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(SPECT ¹æ»ç¼ºµ¿À§¿ø¼Ò, PET ¹æ»ç¼ºµ¿À§¿ø¼Ò, º£Å¸ À̹ÌÅÍ, ¾ËÆÄ À̹ÌÅÍ, ±âŸ Á¦Ç° À¯Çü), ¿ëµµ(Á¾¾çÇÐ, ½ÉÀ庴ÇÐ, ³»ºÐºñÁ¾¾çÇÐ, ½Å°æÇÐ, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(º´¿ø, Áø´Ü¼¾ÅÍ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÃÑ 141°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Radiopharmaceuticals Market to Reach US$14.3 Billion by 2030

The global market for Radiopharmaceuticals estimated at US$7.6 Billion in the year 2024, is expected to reach US$14.3 Billion by 2030, growing at a CAGR of 11.0% over the analysis period 2024-2030. SPECT Radioisotopes, one of the segments analyzed in the report, is expected to record a 10.4% CAGR and reach US$6.2 Billion by the end of the analysis period. Growth in the PET Radioisotopes segment is estimated at 10.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.7 Billion While China is Forecast to Grow at 13.9% CAGR

The Radiopharmaceuticals market in the U.S. is estimated at US$3.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 13.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 8.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.0% CAGR.

Global Radiopharmaceuticals Market - Key Trends & Drivers Summarized

How Are Radiopharmaceuticals Revolutionizing Medical Imaging and Therapy?

Radiopharmaceuticals are transforming the field of medical imaging and therapy, providing advanced diagnostic and treatment options for various diseases, including cancer and cardiovascular conditions. These radioactive compounds are used in nuclear medicine to visualize, diagnose, and treat illnesses at the molecular level. Techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) rely on radiopharmaceuticals to provide detailed images of the body's internal structures and functions. The precision and efficacy of radiopharmaceuticals enable early detection and targeted treatment, improving patient outcomes and reducing side effects compared to conventional therapies.

What Are the Technological and Regulatory Advances in Radiopharmaceuticals?

Technological advancements are significantly enhancing the development and application of radiopharmaceuticals. Innovations in radiochemistry and radiolabeling techniques are enabling the creation of more specific and effective compounds for various diagnostic and therapeutic applications. Advances in imaging technology, such as hybrid PET/MRI and PET/CT systems, are improving the accuracy and resolution of medical imaging. Regulatory frameworks are also evolving to support the safe and efficient development of radiopharmaceuticals. Agencies like the FDA and EMA are establishing guidelines and expedited pathways for the approval of novel radiopharmaceuticals, ensuring timely access to these cutting-edge medical treatments.

How Are Radiopharmaceuticals Impacting Oncology and Cardiology?

In oncology, radiopharmaceuticals are playing a crucial role in both diagnosis and therapy. They enable the detection of tumors at an early stage and monitor the effectiveness of treatment. Therapeutic radiopharmaceuticals, such as radiolabeled monoclonal antibodies, are used to deliver targeted radiation to cancer cells, minimizing damage to surrounding healthy tissue. In cardiology, radiopharmaceuticals are used to assess myocardial perfusion and viability, aiding in the diagnosis and management of coronary artery disease and other cardiac conditions. The ability to obtain precise diagnostic information and deliver targeted therapy is revolutionizing the management of these critical diseases.

What Factors Are Driving the Growth in the Radiopharmaceuticals Market?

The growth in the radiopharmaceuticals market is driven by several factors. The increasing prevalence of cancer and cardiovascular diseases is a major driver, as these conditions require advanced diagnostic and therapeutic solutions. Technological advancements in imaging and radiopharmaceutical development are enhancing the accuracy and efficacy of nuclear medicine procedures. Regulatory support and streamlined approval processes are facilitating the introduction of new radiopharmaceuticals. The growing adoption of personalized medicine is also boosting demand, as radiopharmaceuticals can be tailored to individual patient needs. Additionally, increasing investments in nuclear medicine research and the expansion of healthcare infrastructure are contributing to market growth. These factors collectively ensure the sustained growth and innovation in the radiopharmaceuticals market.

SCOPE OF STUDY:

The report analyzes the Radiopharmaceuticals market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters, Other Product Types); Application (Oncology, Cardiology, Endocrine Tumor, Neurology, Other Applications); End-Use (Hospitals, Diagnostic Centers, Other End-Uses)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 141 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â